West Virginia University
Mechanism of action of NSC3852, a breast cancer differentiation agent
Abstract
dc:description.abstractThe development of tumor cell differentiation agents is new initiative in cancer treatment research. The goal of this project was to identify breast cancer differentiation agents by screening quinoline ring-containing compounds obtained form National Cancer Institute Compound Library. Of six differentiation-inducing quinolines NSC3852 was chosen as a "lead" compound. Our results demonstrate that NSC3852 is an inhibitor of HDAC activity in HeLa and MCF-7 cells nuclear extracts. NSC3852 caused superoxide generation in MCF-7 cells in a NADPH oxidase-dependent fashion, and NSC3852-induced oxidative stress led to the shift in a redox potential of the cells to a more oxidized state. This change in redox status of the cells was accompanied by the accumulation of hypophosphorylated pRb, downregulation of E2F-1 and Myc transcription factor protein levels, and cell differentiation. Superoxide formation in response to NSC3852 exposure caused DNA damage and subsequently apoptosis. MCF-7 cells growth was inhibited. N-Acetyl-L-cysteine (glutathione precursor) pretreated MCF-7 cells were protected against DNA damage, apoptosis, and Rb/E2F/Myc modulation induced by NSC3852. Inhibition of cell growth and induction of cell differentiation in MCF-7 by NSC3852 was partially blocked by NAC. This data suggest that mechanisms in addition to oxidative stress are involved in cell differentiation and growth inhibition by NSC3852 in MCF-7 cells.
Degree
thesis:*- Name thesis:degree_name
- PhD
- Level thesis:degree_level
- Dissertation
- Discipline thesis:degree_discipline
- Physiology, Pharmacology & Neuroscience
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Martirosyan, Anna
Subjects
dc:subject × 3Identifiers
dc:identifier.*- Identifier
- https://researchrepository.wvu.edu/etd/2119